What is the prognosis for patients receiving this treatment?
The prognosis varies depending on the type and stage of cancer, as well as the patient’s response to treatment. Generally, the combination of Epirubicin and Cyclophosphamide has been shown to improve survival rates in breast cancer patients, particularly when used in the early stages of the disease. Ongoing monitoring and follow-up care are essential to manage long-term side effects and detect any recurrence.
